Aarey Drugs & Pharmaceuticals Share Price

87.463.86 (4.62%)

Closed
As On: 22 Jun, 2026, 03:58 PM IST
As On: 22 Jun, 2026, 03:41 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	84.40
High	87.78
Low	83.00
Prev Close	83.60
Volume	2,14,248
VWAP(₹)	86.86

Share Price	Value
Today/Current/Last	87.4687.60
Previous Day	83.6083.43

Aarey Drugs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Aarey Drugs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	189.04	100.61	84.95	103.76	115.64
Total Income Growth (%)	87.90	18.43	-18.12	-10.27	-14.00
Total Expenses	185.98	98.77	82.21	100.99	111.53
Total Expenses Growth (%)	88.30	20.13	-18.60	-9.45	-15.61
EBIT	3.06	1.84	2.74	2.77	4.11
EBIT Growth (%)	66.31	-32.80	-0.85	-32.62	78.48
Profit after Tax (PAT)	1.56	0.57	1.02	1.37	0.47
PAT Growth (%)	173.47	-44.37	-25.35	191.75	-34.53
EBIT Margin (%)	1.62	1.83	3.23	2.67	3.55
Net Profit Margin (%)	0.82	0.57	1.21	1.32	0.41
Basic EPS (₹)	0.55	0.20	0.36	0.48	0.02

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	478.37	483.76	402.58	421.69	495.43
Total Revenue Growth (%)	-1.11	20.16	-4.53	-14.88	39.39
Total Expenses	472.95	477.65	397.24	415.68	485.40
Total Expenses Growth (%)	-0.98	20.24	-4.44	-14.36	39.83
Profit after Tax (PAT)	3.97	4.02	4.68	3.77	6.54
PAT Growth (%)	-1.40	-14.09	24.20	-42.38	0.47
Operating Profit Margin (%)	2.20	2.27	2.45	2.11	2.44
Net Profit Margin (%)	0.84	0.84	1.18	0.90	1.32
Basic EPS (₹)	1.39	1.42	1.67	1.49	2.72

All figures in Rs Cr, unless mentioned otherwise

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	297.25	290.59	303.29	291.32	245.17
Total Assets Growth (%)	2.29	-4.19	4.11	18.82	5.21
Total Liabilities	146.82	152.11	170.52	173.92	131.53
Total Liabilities Growth (%)	-3.48	-10.80	-1.95	32.23	-1.97
Total Equity	150.42	138.48	132.77	117.41	113.64
Total Equity Growth (%)	8.62	4.30	13.08	3.32	14.95
Current Ratio (x)	1.81	1.78	1.70	1.61	1.74
Total Debt to Equity (x)	0.33	0.25	0.24	0.32	0.12
Contingent Liabilities	0.00	-	-	-	-

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	10.14	10.30	-2.99	-1.28	-4.49
Net Cash used in Investing Activities	-12.41	-5.94	-1.70	0.44	-2.20
Net Cash flow from Financing Activities	2.20	-4.48	5.58	1.35	6.23
Net Cash Flow	-0.07	-0.12	0.89	0.51	-0.46
Closing Cash & Cash Equivalent	1.40	1.47	1.59	0.71	0.19
Closing Cash & Cash Equivalent Growth (%)	-5.07	-7.60	125.90	267.78	-70.46
Total Debt/ CFO (x)	4.93	3.38	-10.47	-29.44	-3.15

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 12.41 cr for investing activities which is an YoY increase of 108.96%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	2.63	2.90	3.52	3.21	5.75
Return on Capital Employed (%)	6.84	7.61	7.10	7.20	10.44
Return on Assets (%)	1.33	1.38	1.54	1.29	2.66
Interest Coverage Ratio (x)	2.65	2.73	2.61	3.65	7.01
Asset Turnover Ratio (x)	1.61	1.60	1.33	1.56	2.06
Price to Earnings (x)	36.63	23.87	26.81	15.95	16.08
Price to Book (x)	0.96	0.69	0.94	0.51	0.92
EV/EBITDA (x)	14.57	10.17	13.59	9.29	8.50
EBITDA Margin (%)	2.80	2.68	2.88	2.49	2.84

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Aarey Drugs	54.84	1.65	2.63	6.84	1.33	4.25	2.20	0.84	1.39	1.81	0.33	4.93
Medico Remedies	26.81	4.66	17.37	26.22	8.54	13.57	9.62	6.35	1.58	1.66	0.25	3.21
Medicamen Bio	28.46	1.12	3.49	5.45	2.59	11.78	7.82	4.95	7.22	2.54	0.17	-1.44
Ambalal Sarabhai	13.70	1.54	11.24	12.59	6.33	5.90	11.36	8.59	2.32	1.27	0.33	3.85
Lyka Labs	-24.29	2.68	-10.85	-7.00	-5.74	10.88	-6.57	-8.12	-2.81	1.17	0.52	9.22
Add More

Annual Ratios (%)

Choose from Peers

Nectar Lifesc
Brooks Labs
Natural Capsule
Alpa Labs
Krebs Biochem

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Aarey Drugs Stock Performance	4.62	-4.21	-0.81	11.39	64.18	212.36	0.00
Medico Remedies Stock Performance	-0.61	-2.24	3.29	-7.73	-23.63	-48.89	0.00
Medicamen Bio Stock Performance	-0.40	-16.11	-12.80	-27.87	-47.22	-65.11	0.00
Ambalal Sarabhai Stock Performance	-0.38	2.88	-0.41	0.00	0.00	0.00	0.00
Lyka Labs Stock Performance	1.33	9.39	15.59	8.54	-42.07	-29.98	13.03
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	1,06,92,443	37.71 %	-1.35
Pledge	0	0.00 %	0.00
FII	11,84,001	4.18 %	0.31
Others	1,64,77,859	58.11 %	1.03

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	37.71	39.06	44.80	44.80
Pledge	0.00	0.00	0.00	0.00
FII	4.18	3.86	1.13	1.97
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	58.11	57.08	54.07	53.23

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 29, 2026
Board Meeting
Audited Results
May 29, 2026
Board Meeting
Quarterly Results
Feb 04, 2026

Board Meetings

Announced on	Meeting on
May 29, 2026	May 30, 2026
Audited Results
May 29, 2026	May 29, 2026
Audited Results
Feb 04, 2026	Feb 11, 2026
Quarterly Results
Nov 10, 2025	Nov 13, 2025
Quarterly Results
Aug 07, 2025	Aug 13, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
Nov 30, 2018 Dec 13, 2018 1%
Bonus
Announced on Ex-Date
May 18, 2012 Jun 25, 2012
Bonus Ratio: 1 share(s) for every 5 shares held
Splits
Announced on Ex-Date
Aug 14, 2017 -
Split: Old FV10.0| New FV:1.0
Rights
Announced on Ex-Date
Dec 17, 2009 Jan 19, 2012
Rights ratio: 2 share for every 1 held at a price of Rs 25.0
AGM/EGM Meetings
Announced on Meeting on
Sep 09, 2025 Sep 29, 2025
-
Dec 09, 2024 Jan 02, 2025
-
Aug 13, 2024 Sep 30, 2024
Book closure from Sep 24, 2024 to Sep 30, 2024
Dec 06, 2023 Dec 29, 2023
-
Aug 14, 2023 Sep 05, 2023
A.G.M.

Announced on	Ex-Date	Dividend%
Nov 30, 2018	Dec 13, 2018	1%

Announced on	Ex-Date
May 18, 2012	Jun 25, 2012
Bonus Ratio: 1 share(s) for every 5 shares held

Announced on	Ex-Date
Aug 14, 2017	-
Split: Old FV10.0\| New FV:1.0

Announced on	Ex-Date
Dec 17, 2009	Jan 19, 2012
Rights ratio: 2 share for every 1 held at a price of Rs 25.0

Announced on	Meeting on
Sep 09, 2025	Sep 29, 2025
-
Dec 09, 2024	Jan 02, 2025
-
Aug 13, 2024	Sep 30, 2024
Book closure from Sep 24, 2024 to Sep 30, 2024
Dec 06, 2023	Dec 29, 2023
-
Aug 14, 2023	Sep 05, 2023
A.G.M.

About Aarey Drugs

Aarey Drugs & Pharmaceuticals Ltd., incorporated in the year 1990, is a Small Cap company (having a market cap of Rs 247.99 Crore) operating in Pharmaceuticals sector.

Aarey Drugs & Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Commission for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Standalone Total Income of Rs 189.04 Crore, up 87.90 % from last quarter Total Income of Rs 100.61 Crore and up 63.48 % from last year same quarter Total Income of Rs 115.64 Crore. Company has reported net profit after tax of Rs 1.56 Crore in latest quarter.

The company’s top management includes Mr.Mihir R Ghatalia, Mr.Nimit Rajesh Ghatalia, Mr.Anil Mandal, Mr.Chetan K Mehta, Mr.Lalit Radhakrishna Tulsiani, Ms.Bina Rajesh Ghatalia, Mr.Mira M Ghatalia, Mr.Kailash Chand Jethlia. Company has Motilal & Associates LLP as its auditors. As on 31-03-2026, the company has a total of 2.84 Crore shares outstanding.

Aarey Drugs Share Price Today is Rs. 87.46. On previous day, the Aarey Drugs Share Price (NSE) closed at Rs. 81.89, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 37.71% of the stake in Aarey Drugs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Aarey Drugs stocks was 4.18% as compared to 3.86% in Dec 2025 with increase of 0.32%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Aarey Drugs shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Aarey Drugs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Aarey Drugs Dividend: Ever since 1990, Aarey Drugs dividends has been paid out around 1 times. As on 22 Jun, 2026, 03:58 PM IST, The overall dividend yield for Aarey Drugs stands at 0.0%. The last dividend paid was on December 13, 2018 (Rs. 0.1). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 1.59.

Aarey Drugs Bonus: The most recent bonus issue had been in year June 25, 2012 around 13 years ago at 5 : 1 ratio. The first bonus issue was announced in May 2012.

Stock Forecast:
After showing 189.04 Cr. of sales and 87.9% of quarterly net profit, there have been multiple ups and downs in the Aarey Drugs stock prices in the past few weeks. For example, Aarey Drugs stock price on 12th of June 2026 was around Rs. 77.85. Aarey Drugs share price now stands at an average of Rs. 87.46. Judging by last week's performance, stock is in up trend.

Aarey Drugs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Aarey Drugs share.

Historical Prices and Performance:
Aarey Drugs, incorporated in 1990 is a Small Cap company (with a market cap of Rs. 237.04) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Aarey Drugs stock was 2.63%, 2.9%, 3.52%, 3.21% and 5.75% respectively.
The Aarey Drugs share gave a 3 year return of 140.23% as compared to Nifty 50 which gave a return of 28.03%.
Aarey Drugs announced 1.0% final dividend on December 13, 2018.

Key Metrics:
PE Ratio of Aarey Drugs is 51.35
Prices/Sales Ratio of Aarey Drugs is 0.31
Price/Book Ratio of Aarey Drugs is 1.54

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Aarey Drugs, major competitors and peers include Medicamen Bio, Ambalal Sarabhai, Lyka Labs and Nectar Lifesc. As of Dec 2025, the dividend yield of Aarey Drugs stands at 0.0% while Medicamen Bio, Ambalal Sarabhai, Lyka Labs and Nectar Lifesc stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 51.35 and 1.54 respectively.

Leadership of Aarey Drugs :
Mira M Ghatalia is Chief Financial Officer
Kailash Chand Jethlia is Co. Secretary & Compl. Officer
Mihir R Ghatalia is Chairman & Managing Director
Nimit Rajesh Ghatalia is Executive Director
Bina Rajesh Ghatalia is Woman Director
Chetan K Mehta is Independent Director
Anil Mandal is Independent Director
Lalit Radhakrishna Tulsiani is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

E-34, M.I.D.C.,Tarapur,Thane, Maharashtra - 401506

Contact

investorgrievance@aareydrugs.com

http://www.aareydrugs.com

PE Ratio(x)	54.84
EPS - TTM(₹)	1.59
MCap(₹ Cr.)	247.99
MCap Rank	102
PB Ratio(x)	1.58
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	100.00
52W Low(₹)	50.31
MCap/Sales	0.31
Beta(1 Month)	-
BV/Share(₹)	53.05

PE Ratio(x)	54.93
EPS - TTM(₹)	1.59
MCap(₹ Cr.)	248.38
MCap Rank	115
PB Ratio(x)	1.60
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	100.00
52W Low(₹)	50.40
MCap/Sales	0.31
Beta(1 Month)	0.28
BV/Share(₹)	53.05

1 Day	4.62%
1 Month	4.44%
3 Months	26.24%
1 Year	53.57%
3 Years	161.46%
5 Years	N.A.

1 Day	4.99%
1 Month	3.06%
3 Months	27.12%
1 Year	54.72%
3 Years	160.87%
5 Years	164.65%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Aarey Drugs & Pharmaceuticals Share Price

Key Metrics

Aarey Drugs share price insights

Aarey Drugs Share Price Returns

Aarey Drugs Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Aarey Drugs Top Searches

Corporate Actions

About Aarey Drugs

Executive Leadership

Auditors

FAQs about Aarey Drugs share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News